Updated on 2026/04/08

写真a

 
KIDA Ryotaro
 
Organization
Hospital Clinical Departments Internal Medicine [Respiratory system ,Cranial nerves]
External link

Research Interests

  • lung cancer

  • びまん性肺疾患

Research Areas

  • Life Science / Tumor biology

Education

  • Asahikawa Medical College   School of Medicine   Medical Course

    2009.4 - 2015.3

    　 More details

Research History

  • Asahikawa Medical College   Assistant Professor

    2026.4

    　 More details

  • 旭川医科大学病院   がん遺伝子診療部

    2025.3

    　 More details

  • Asahikawa Medical College

    2025.3 - 2026.3

    　 More details

  • 北海道立北見病院   呼吸器内科   患者支援室長

    2023.4 - 2025.3

    　 More details

  • 旭川医科大学病院   呼吸器センター   医員

    2020.4 - 2023.3

    　 More details

  • 市立稚内病院   内科   副医長

    2019.4 - 2020.3

    　 More details

  • 名寄市立総合病院   呼吸器内科   医員

    2017.4 - 2019.3

    　 More details

▼display all

Professional Memberships

▼display all

Papers

  • Mathematical model for nosocomial coronavirus infection disease 2019 transmission and patient isolation in hospital wards: A modeling study

    Yasuhiro Umekage, Ryota Shigaki, Ryotaro Kida, Ryohei Yoshida, Yoshinori Minami, Yoshinobu Ohsaki, Takaaki Sasaki

    American Journal of Infection Control   2025.11

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.ajic.2025.11.022

    researchmap

  • Sotorasib resistance in KRAS G12C-mutant invasive mucinous adenocarcinoma with implications for VEGF-A

    Hiraku Yanada, Ryohei Yoshida, Ryotaro Kida, Kiichi Nitanai, Maya Ikeda, Kazunori Nagasue, Taeka Naraoka, Masashi Ueda, Takashi Watanabe, Ryota Shigaki, Yasuhiro Umekage, Yoshinori Minami, Toshihiro Nagato, Manami Hayashi, Sayaka Yuzawa, Mishie Tanino, Takaaki Sasaki

    npj Precision Oncology   9 ( 1 )   2025.5

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    Abstract

    Invasive mucinous adenocarcinoma (IMA) is a rare subtype of lung adenocarcinoma with a poor prognosis. Compared to non-small cell lung cancer, IMA more frequently harbors KRAS mutations in the order p.G12V, p.G12D, and p.G12C. This report describes a patient with a KRAS p.G12C-mutant IMA treated with sotorasib. To date, no studies have investigated the therapeutic efficacy or resistance mechanisms of sotorasib in IMA. The patient was treated with carboplatin and pemetrexed, followed by sotorasib upon disease progression. While the primary lung lesions responded well, metastatic thoracic lymph node lesions continued to increase. A pathological autopsy was performed with the family’s consent to investigate potential resistance mechanisms. RNA sequencing and additional analyses revealed increased VEGF-A expression in metastatic lymph node lesions, suggesting a role in sotorasib resistance. These findings provide insights into the potential molecular mechanisms underlying treatment resistance in KRAS p.G12C-mutant IMA.

    DOI： 10.1038/s41698-025-00953-2

    researchmap

    Other Link： https://www.nature.com/articles/s41698-025-00953-2

  • Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancer

    Daisuke Morinaga, Kana Hashimoto, Hajime Asahina, Hisashi Tanaka, Osamu Honjo, Toshiyuki Harada, Hiroshi Yokouchi, Hajime Kikuchi, Ryota Shigaki, Taichi Takashina, Keiichi Nakamura, Yasutaka Kawai, Mamoru Takahashi, Ryotaro Kida, Noriaki Sukoh, Kenichiro Ito, Ayumu Takahashi, Fumihiro Hommura, Yoshihito Ohhara, Megumi Furuta, Satoshi Konno, Yukio Hosomi, Satoshi Oizumi

    Respiratory Investigation   63 ( 3 )   373 - 382   2025.5

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.resinv.2025.03.008

    researchmap

  • Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)

    Kana Hashimoto, Daisuke Morinaga, Hajime Asahina, Mina Ishidoya, Hajime Kikuchi, Hiroshi Yokouchi, Toshiyuki Harada, Osamu Honjo, Ryota Shigaki, Taichi Takashina, Yuka Fujita, Mamoru Takahashi, Yasutaka Kawai, Ryotaro Kida, Kenichiro Ito, Noriaki Sukoh, Ayumu Takahashi, Fumihiro Hommura, Yoshihito Ohhara, Megumi Furuta, Satoshi Konno, Yukio Hosomi, Satoshi Oizumi

    JTO Clinical and Research Reports   5 ( 11 )   100715 - 100715   2024.11

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.jtocrr.2024.100715

    researchmap

  • Viability and diagnostic potential of tissues obtained through cryobiopsy

    Ryotaro Kida, Ryohei Yoshida, Kiichi Nitanai, Akari Yagita, Taeka Naraoka, Hiraku Yanada, Ryota Shigaki, Toshiyuki Tenma, Chie Mori, Yasuhiro Umekage, Mamiko Mitsumoto, Mishie Tanino, Yoshinori Minami, Takaaki Sasaki

    Respiratory Investigation   2024.11

    　More details

    Authorship：Lead author   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.resinv.2024.10.011

    researchmap

  • Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report

    Kazunori Nagasue, Ryotaro Kida, Ryota Shigaki, Kiichi Nitanai, Akari Yagita, Hiraku Yanada, Yasuhiro Umekage, Chie Mori, Yoshinori Minami, Takuya Funayama, Masayo Yamamoto, Mishie Tanino, Ryohei Yoshida, Takaaki Sasaki

    Oncology Letters   29 ( 1 )   2024.10

    　More details

    Authorship：Corresponding author   Publishing type：Research paper (scientific journal)   Publisher：Spandidos Publications  

    DOI： 10.3892/ol.2024.14777

    researchmap

  • Case Report: Case series: association between blood concentration and side effects of sotorasib

    Ryota Shigaki, Ryohei Yoshida, Akari Yagita, Kazunori Nagasue, Taeka Naraoka, Kiichi Nitanai, Hiraku Yanada, Toshiyuki Tenma, Ryotaro Kida, Yasuhiro Umekage, Chie Mori, Yoshinori Minami, Hideki Sato, Kuninori Iwayama, Yasuhisa Hashino, Masahide Fukudo, Takaaki Sasaki

    Frontiers in Oncology   13   2023.11

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Frontiers Media SA  

    Introduction

    Sotorasib is a crucial therapeutic agent for patients with non-small cell lung cancer (NSCLC) harboring the KRAS p.G12C mutation. Despite its efficacy, the relationship between blood sotorasib concentrations and side effects remains largely unexplored.

    Methods

    This study enrolled five patients with KRAS p.G12C-positive NSCLC treated with sotorasib (LUMAKRAS<sup>®</sup> Tablets, Amgen, Japan) between July 2022 and February 2023 at Asahikawa Medical University Hospital. Blood sotorasib levels were monitored, and their association with adverse events was examined, with no adjustments made to drug dosages based on these levels.

    Results

    Variable blood sotorasib levels were observed among the participants. Notably, one patient developed interstitial pneumonitis, although a definitive attribution to sotorasib was uncertain due to prior pembrolizumab treatment. The study revealed no consistent association between blood sotorasib levels and adverse events or therapeutic outcomes, with some patients experiencing severe side effects at higher concentrations, while others did not.

    Conclusion

    Preliminary findings suggested that monitoring blood sotorasib levels may aid in anticipating adverse events in this small cohort. However, future studies with larger sample sizes and extended follow-up periods are required to validate these initial observations. Such studies could potentially offer insights into personalized dosing strategies, thereby mitigating adverse effects and enhance patient care for individuals with KRAS p.G12C-positive NSCLC.

    DOI： 10.3389/fonc.2023.1269991

    researchmap

  • Detection of resistance mutations in patients with anaplastic lymphoma kinase-rearranged lung cancer through liquid biopsy

    Takaaki Sasaki, Ryohei Yoshida, Kiichi Nitanai, Takashi Watanabe, Toshiyuki Tenma, Ryotaro Kida, Chie Mori, Yasuhiro Umekage, Noriko Hirai, Yoshinori Minami, Shunsuke Okumura

    Translational Lung Cancer Research   12 ( 7 )   1445 - 1453   2023.7

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：AME Publishing Company  

    DOI： 10.21037/tlcr-22-671

    researchmap

  • Does the natural course of COVID‐19 infection include radiographic cystic changes?

    Noriko Hirai, Ryotaro Kida, Hiraku Yanada

    Clinical Case Reports   10 ( 1 )   2022.1

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    Abstract

    A patient with late phase of COVID‐19 pneumonia presented peripheral cystic features on chest computed tomography, which were spontaneously resolved with no antibiotic therapy or surgery. Physicians should pay attention to follow up the late phase of COVID‐19 pneumonia for better understanding its progression and clinical course.

    DOI： 10.1002/ccr3.5036

    researchmap

    Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ccr3.5036

▼display all

Presentations

  • 初回薬物療法でのオシメルチニブによる血球減少の解析

    第66回日本肺癌学会  2025.11 

    　More details

    Presentation type：Poster presentation  

    researchmap

Awards

  • 特別症(若手優秀演題)

    2024.6   日本呼吸器内視鏡学会   クライオ生検で採取した検体でフローサイトメトリーは可能か？

    　More details